vs
Innoviva, Inc.（INVA）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Innoviva, Inc.的季度营收约是RE/MAX Holdings, Inc.的1.6倍（$114.6M vs $71.1M），Innoviva, Inc.净利率更高（143.2% vs 2.0%，领先141.2%），Innoviva, Inc.同比增速更快（24.8% vs -1.8%），过去两年Innoviva, Inc.的营收复合增速更高（21.6% vs -4.7%）
Innoviva Inc是一家专注于呼吸道疾病、传染病及重症护理领域处方治疗药物研发、商业化及特许权使用费管理的医疗保健企业，与全球领先制药商合作，为北美、欧洲等核心市场的患者提供哮喘、慢性阻塞性肺疾病等病症的治疗方案。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
INVA vs RMAX — 直观对比
营收规模更大
INVA
是对方的1.6倍
$71.1M
营收增速更快
INVA
高出26.7%
-1.8%
净利率更高
INVA
高出141.2%
2.0%
两年增速更快
INVA
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.6M | $71.1M |
| 净利润 | $164.2M | $1.4M |
| 毛利率 | 66.0% | — |
| 营业利润率 | 34.0% | 13.1% |
| 净利率 | 143.2% | 2.0% |
| 营收同比 | 24.8% | -1.8% |
| 净利润同比 | 707.4% | -75.2% |
| 每股收益（稀释后） | $2.19 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INVARMAX
| Q4 25 | $114.6M | $71.1M | ||
| Q3 25 | $107.8M | $73.2M | ||
| Q2 25 | $100.3M | $72.8M | ||
| Q1 25 | $88.6M | $74.5M | ||
| Q4 24 | $91.8M | $72.5M | ||
| Q3 24 | $89.5M | $78.5M | ||
| Q2 24 | $99.9M | $78.5M | ||
| Q1 24 | $77.5M | $78.3M |
净利润INVARMAX
| Q4 25 | $164.2M | $1.4M | ||
| Q3 25 | $89.9M | $4.0M | ||
| Q2 25 | $63.7M | $4.7M | ||
| Q1 25 | $-46.6M | $-2.0M | ||
| Q4 24 | $20.3M | $5.8M | ||
| Q3 24 | $1.2M | $966.0K | ||
| Q2 24 | $-34.7M | $3.7M | ||
| Q1 24 | $36.5M | $-3.4M |
毛利率INVARMAX
| Q4 25 | 66.0% | — | ||
| Q3 25 | 70.1% | — | ||
| Q2 25 | 82.9% | — | ||
| Q1 25 | 82.7% | — | ||
| Q4 24 | 85.1% | — | ||
| Q3 24 | 81.6% | — | ||
| Q2 24 | 85.1% | — | ||
| Q1 24 | 77.5% | — |
营业利润率INVARMAX
| Q4 25 | 34.0% | 13.1% | ||
| Q3 25 | 32.1% | 25.0% | ||
| Q2 25 | 48.6% | 19.3% | ||
| Q1 25 | 46.7% | 7.2% | ||
| Q4 24 | 47.0% | 5.9% | ||
| Q3 24 | 48.3% | 19.4% | ||
| Q2 24 | 54.7% | 20.6% | ||
| Q1 24 | 33.3% | 5.8% |
净利率INVARMAX
| Q4 25 | 143.2% | 2.0% | ||
| Q3 25 | 83.4% | 5.4% | ||
| Q2 25 | 63.5% | 6.4% | ||
| Q1 25 | -52.6% | -2.6% | ||
| Q4 24 | 22.1% | 8.0% | ||
| Q3 24 | 1.4% | 1.2% | ||
| Q2 24 | -34.7% | 4.7% | ||
| Q1 24 | 47.1% | -4.3% |
每股收益（稀释后）INVARMAX
| Q4 25 | $2.19 | — | ||
| Q3 25 | $1.08 | — | ||
| Q2 25 | $0.77 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $0.43 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | $0.46 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $550.9M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $1.2B | $452.4M |
| 总资产 | $1.6B | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资INVARMAX
| Q4 25 | $550.9M | $118.7M | ||
| Q3 25 | $476.5M | $107.5M | ||
| Q2 25 | $397.5M | $94.3M | ||
| Q1 25 | $319.1M | $89.1M | ||
| Q4 24 | $305.0M | $96.6M | ||
| Q3 24 | $260.6M | $83.8M | ||
| Q2 24 | $217.0M | $66.1M | ||
| Q1 24 | $178.4M | $82.1M |
总债务INVARMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益INVARMAX
| Q4 25 | $1.2B | $452.4M | ||
| Q3 25 | $1.0B | $448.1M | ||
| Q2 25 | $714.8M | $442.4M | ||
| Q1 25 | $646.9M | $433.5M | ||
| Q4 24 | $691.2M | $429.5M | ||
| Q3 24 | $668.5M | $423.1M | ||
| Q2 24 | $665.5M | $418.4M | ||
| Q1 24 | $703.7M | $412.0M |
总资产INVARMAX
| Q4 25 | $1.6B | $582.5M | ||
| Q3 25 | $1.4B | $582.2M | ||
| Q2 25 | $1.3B | $574.8M | ||
| Q1 25 | $1.3B | $571.4M | ||
| Q4 24 | $1.3B | $581.6M | ||
| Q3 24 | $1.2B | $578.6M | ||
| Q2 24 | $1.2B | $571.4M | ||
| Q1 24 | $1.3B | $566.7M |
负债/权益比INVARMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.5M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | — | $33.5M |
| 自由现金流率自由现金流/营收 | — | 47.1% |
| 资本支出强度资本支出/营收 | — | 10.4% |
| 现金转化率经营现金流/净利润 | 0.33× | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流INVARMAX
| Q4 25 | $54.5M | $40.9M | ||
| Q3 25 | $49.7M | $17.7M | ||
| Q2 25 | $44.1M | $4.6M | ||
| Q1 25 | $48.6M | $5.7M | ||
| Q4 24 | $59.2M | $59.7M | ||
| Q3 24 | $48.7M | $17.6M | ||
| Q2 24 | $43.7M | $15.9M | ||
| Q1 24 | $37.0M | $9.4M |
自由现金流INVARMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | $48.4M | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率INVARMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | 54.1% | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度INVARMAX
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 0.0% | 9.1% | ||
| Q3 24 | 0.3% | 1.7% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.0% | 3.3% |
现金转化率INVARMAX
| Q4 25 | 0.33× | 28.39× | ||
| Q3 25 | 0.55× | 4.45× | ||
| Q2 25 | 0.69× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.91× | 10.28× | ||
| Q3 24 | 40.14× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | 1.01× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INVA
| Royalty | $54.9M | 48% |
| Xacduro | $32.1M | 28% |
| Giapreza | $19.6M | 17% |
| Xerava | $7.3M | 6% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
